Pharmacological reactivation of p53 as a strategy to treat cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The TP53 tumor suppressor gene is the most frequently inactivated gene in cancer.
• p53 ablation is essential for tumor development and maintenance.
• Restoring p53 function can suppress established tumors.

Purpose of the Study:

• To review recent advances in developing small molecules that restore p53 function.
• To discuss various mechanisms for p53 reactivation.
• To consider the clinical applications of p53-targeting compounds.

Main Methods:

• Review of recent scientific literature on p53 reactivation strategies.
• Analysis of small molecules targeting mutant and wild-type p53.
• Discussion of clinical trial data for p53-targeting agents.

Main Results:

• Small molecules can restore p53 function through diverse mechanisms.
• Apr-246 stabilizes mutant p53 folding and is in Phase II clinical trials.
• Mdm2 inhibitors and other compounds targeting the p53 pathway are under clinical investigation.

Conclusions:

• p53 reactivation by small molecules is a viable and efficient cancer treatment strategy.
• Targeting the p53 pathway holds significant therapeutic potential for various cancers.
• Ongoing research and clinical trials are advancing the application of p53-targeting drugs.